S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
NASDAQ:AZYO

Aziyo Biologics - AZYO Stock Forecast, Price & News

$4.59
+0.10 (+2.23%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$4.41
$4.82
50-Day Range
$3.48
$7.40
52-Week Range
$3.37
$9.01
Volume
20,264 shs
Average Volume
38,584 shs
Market Capitalization
$63.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.17

Aziyo Biologics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
143.3% Upside
$11.17 Price Target
Short Interest
Healthy
0.11% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.07mentions of Aziyo Biologics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$3.64 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.60) to ($2.01) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.61 out of 5 stars

Medical Sector

103rd out of 1,053 stocks

Biological Products, Except Diagnostic Industry

19th out of 170 stocks


AZYO stock logo

About Aziyo Biologics (NASDAQ:AZYO) Stock

Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Receive AZYO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aziyo Biologics and its competitors with MarketBeat's FREE daily newsletter.

AZYO Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
A Look Into Aziyo Biologics' Debt
What Does Aziyo Biologics' Debt Look Like?
Aziyo Biologics Reports Strong Third Quarter 2022 Revenue
Preview: Aziyo Biologics's Earnings
See More Headlines
Receive AZYO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aziyo Biologics and its competitors with MarketBeat's FREE daily newsletter.

AZYO Company Calendar

Last Earnings
11/14/2022
Today
2/02/2023
Next Earnings (Estimated)
3/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AZYO
Employees
176
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.17
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+143.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-24,830,000.00
Pretax Margin
-76.97%

Debt

Sales & Book Value

Annual Sales
$47.38 million
Book Value
$1.00 per share

Miscellaneous

Free Float
8,278,000
Market Cap
$63.22 million
Optionable
Not Optionable
Beta
-0.19

Key Executives

  • Mr. Kevin L. Rakin M.B.A (Age 61)
    M.S., Exec. Chairman
    Comp: $77.5k
  • Dr. C. Randal Mills Ph.D. (Age 50)
    Co-Founder, Pres & CEO and Director
    Comp: $65k
  • Mr. Matthew B. FergusonMr. Matthew B. Ferguson (Age 54)
    Chief Financial Officer
    Comp: $356.64k
  • Mr. Thomas EngleseMr. Thomas Englese (Age 48)
    Chief Commercial Officer
    Comp: $396.11k
  • Ms. Erica Elchin
    VP of Global Operations
  • Dr. Michelle LeRoux Williams Ph.D. (Age 47)
    Chief Scientific Officer
  • Ms. Courtney Guyer
    VP of Marketing
  • Dr. Sonali Fonseca Ph.D.
    Head of Emerging Bus.es
  • Mr. Jeffry D. Hamet
    Sr. VP of Fin., Treasurer & Sec.













AZYO Stock - Frequently Asked Questions

Should I buy or sell Aziyo Biologics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aziyo Biologics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AZYO shares.
View AZYO analyst ratings
or view top-rated stocks.

What is Aziyo Biologics' stock price forecast for 2023?

4 equities research analysts have issued twelve-month target prices for Aziyo Biologics' stock. Their AZYO share price forecasts range from $10.00 to $13.00. On average, they expect the company's stock price to reach $11.17 in the next twelve months. This suggests a possible upside of 143.3% from the stock's current price.
View analysts price targets for AZYO
or view top-rated stocks among Wall Street analysts.

How have AZYO shares performed in 2023?

Aziyo Biologics' stock was trading at $4.25 at the beginning of 2023. Since then, AZYO stock has increased by 8.0% and is now trading at $4.59.
View the best growth stocks for 2023 here
.

Are investors shorting Aziyo Biologics?

Aziyo Biologics saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 6,500 shares, a decline of 64.1% from the December 31st total of 18,100 shares. Based on an average daily volume of 32,700 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.1% of the shares of the company are sold short.
View Aziyo Biologics' Short Interest
.

When is Aziyo Biologics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our AZYO earnings forecast
.

How were Aziyo Biologics' earnings last quarter?

Aziyo Biologics, Inc. (NASDAQ:AZYO) issued its quarterly earnings data on Monday, November, 14th. The company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.66) by $0.07. The business earned $12.39 million during the quarter, compared to analyst estimates of $12.20 million. Aziyo Biologics had a negative trailing twelve-month return on equity of 1,819.23% and a negative net margin of 77.08%.

What guidance has Aziyo Biologics issued on next quarter's earnings?

Aziyo Biologics updated its fourth quarter 2022 earnings guidance on Monday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $12.50 million-$12.70 million, compared to the consensus revenue estimate of $12.49 million.

When did Aziyo Biologics IPO?

(AZYO) raised $49 million in an initial public offering on Thursday, October 8th 2020. The company issued 2,900,000 shares at $16.00-$18.00 per share. Piper Sandler and Cowen acted as the underwriters for the IPO and Cantor and Truist Securities ​ were co-managers.

What is Aziyo Biologics' stock symbol?

Aziyo Biologics trades on the NASDAQ under the ticker symbol "AZYO."

Who are Aziyo Biologics' major shareholders?

Aziyo Biologics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Perkins Capital Management Inc. (1.88%). Insiders that own company stock include Brigid Makes, David Colpman, Highcape Capital, LP, Matthew Ferguson, Ronald K Lloyd and Thomas Englese.
View institutional ownership trends
.

How do I buy shares of Aziyo Biologics?

Shares of AZYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aziyo Biologics' stock price today?

One share of AZYO stock can currently be purchased for approximately $4.59.

How much money does Aziyo Biologics make?

Aziyo Biologics (NASDAQ:AZYO) has a market capitalization of $63.20 million and generates $47.39 million in revenue each year. The company earns $-24,830,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis.

How many employees does Aziyo Biologics have?

The company employs 176 workers across the globe.

How can I contact Aziyo Biologics?

The official website for the company is www.aziyobiologics.com. The company can be reached via phone at 240-247-1170, via email at ir@aziyo.com, or via fax at 510-307-9896.

This page (NASDAQ:AZYO) was last updated on 2/2/2023 by MarketBeat.com Staff